Skip to main content

SIMPLAAFY Patient Selection

Who is a SIMPLAAFY Patient?

Qualified trial patients must meet all the following criteria.

 Patient is at increased risk for stroke systemic embolism based on CHA2DS2- VASc scores and is recommended for anticoagulation therapy*. 

 Patient is deemed by their physicians to be suitable for oral anticoagulation (OAC). 

 Patient has an appropriate rationale to seek a non-pharmacologic alternative to OAC, taking into account the safety and effectiveness of the device compared to OAC. 

Patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial.

Patient is able and willing to return for required follow-up visits and examinations.

* Medicare patients need to meet the CMS NCD 20.34.

  
  
Find a Trial Site

Find a Trial Site

Boston Scientific has selected US sites to be SIMPLAAFY investigational centers. If you have a candidate in mind, view the active trial list provided by clinicaltrials.gov, and reach out to a study physician near you to discuss next steps for referral.

WATCHMAN FLX Pro Device Brief Summary
Top